

Table S1. Diameter (in mm) of inhibition zone found for the LAB strains tested with 15 antibiotics.

	A1	A2	A3	A4	A5	A6	A7	A8	A9	A10	A11	A12	A13	A14
<i>Inhibitors of cell wall synthesis</i>														
<i>Ampicillin</i>	29(S*)	30(S)	30(S)	35(S)	34(S)	35(S)	30(S)	0 (R*)	0 (R)	36 (S)	0 (R)	34 (S)	0 (R)	0 (R)
<i>Penicillin G</i>	30(S)	38(S)	32(S)	36 (S)	35 (S)	36 (S)	35 (S)	36 (S)	38 (S)	34 (S)	11(R)	26 (S)	34 (S)	8 (I*)
<i>Polymixin B sulfate</i>	12(S)	9(S)	11(S)	18(S)	17 (S)	15.5 (S)	18 (S)	18 (S)	17 (S)	16 (S)	12(S)	18(S)	17 (S)	17(S)
<i>Inhibitors of proteins synthesis</i>														
<i>Chloromphenicol</i>	27(S)	32(S)	37(S)	35(S)	26(S)	32(S)	30(S)	34(S)	31(S)	32(S)	30(S)	30(S)	32(S)	32(S)
<i>Erythromycin</i>	20(S)	22(S)	0 (R)	22(S)	12 (S)	12 (S)	12 (S)	8(I)	8(I)	26(S)	18(S)	0 (R)	12(S)	10(S)
<i>Gentamicin</i>	0 (R)	8(I)	8(I)	8(I)	8(I)	10(S)	8(I)	24 (S)	22 (S)	11(S)	24 (S)	8(I)	18(S)	23 (S)
<i>Kanamycin</i>	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	26 (S)	31 (S)	0 (R)	26 (S)
<i>Oxytetracyclin</i>	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)
<i>Streptomycin</i>	0 (R)	7 (I)	0 (R)	18 (S)	14 (S)	13 (S)	15 (S)	20.5(S)	19(S)	14 (S)	20(S)	15 (S)	19(S)	18(S)
<i>Tetracyclin</i>	24(S)	26(S)	30(S)	20(S)	36(S)	32(S)	36(S)	15(S)	12(S)	34(S)	10(S)	36(S)	12 (S)	12(S)
<i>Inhibitors of nucleic acid synthesis</i>														
<i>Ciprofloxacin</i>	0 (R)	0 (R)	0 (R)	16(S)	18(S)	28 (S)	28 (S)	26 (S)	22 (S)	18.5(S)	24 (S)	18.5(S)	24 (S)	24 (S)
<i>Levofloxacin</i>	17(S)	18(S)	17(S)	26(S)	34(S)	28(S)	34(S)	30(S)	33(S)	30(S)	30(S)	36(S)	34(S)	30(S)
<i>Nalidixic acid</i>	0 (R)	0 (R)	0 (R)	0 (R)	0 (R)	12(S)	10 (S)	0 (R)	10(S)	10 (S)	16 (S)	32 (S)	8 (I)	18 (S)
<i>Norfloxacin</i>	0 (R)	0 (R)	0 (R)	17(S)	18(S)	19(S)	16(S)	18(S)	19(S)	19(S)	20(S)	18(S)	18(S)	20(S)
<i>Rifampicin</i>	32(S)	31 (S)	28(S)	30 (S)	30 (S)	28 (S)	32 (S)	28 (S)	30 (S)	29 (S)	23 (S)	24 (S)	31 (S)	24 (S)

* The definition of antibiotic-resistant (R), -susceptible (S) and –intermediate (I) of a given bacterial strain is based on the diameter of inhibition as compared to those reported by the EFSA (European Food Safety Authority, 2003 #10)

Table S2. Survival rates (%) * of the LAB strains exposed for 0 (T0), 1 (T1) and 3 (T3) h to pepsin at pH 2 or pH 3 and of the LAB strains exposed for 0 (T0) and 4 (T4) h to pancreatin.

	pepsin (pH=2)			pepsin (pH=3)			pancreatin	
	T0	T1	T3	T0	T1	T3	T0	T4
<i>L. paraplantarum</i> A1	89±8.9 ^a	79±5.0 ^a	77±1.1 ^b	65±1.4 ^A	59±2.3 ^A	58±2.0 ^A	71±2.6A	46±3.3B
<i>L. plantarum</i> A2	81±1.6 ^a	75±1.1 ^a	68±2.5 ^b	68±1.6 ^A	64±2.1 ^A	60±3.5 ^A	65±2.4A	58±4.2A
<i>L. plantarum</i> A3	80±1.2 ^a	74±1.2 ^a	63±2.3 ^a	62 ±2.4 ^A	76±1.4 ^A	51 ±2.1 ^B	57±2.0A	53±3.4A
<i>E. faecalis</i> A4	75±2.0 ^a	67±2.7 ^a	62±1.6 ^a	87±5.2 ^A	69±1.2 ^A	66±2.1 ^A	71±2.1A	87±6.1A
<i>E. faecalis</i> A5	49±2.9 ^a	47±1.8 ^a	41±2.6 ^a	90±5.0 ^A	57±3.2 ^A	48±8.9 ^B	74±1.5A	87±6.6A
<i>E. faecalis</i> A6	72±1.5 ^a	56±0.0 ^a	45±1.1 ^b	90±6.3 ^A	77±1.4 ^A	50±2.7 ^C	75±1.6A	86±7.0A
<i>E. faecalis</i> A7	65±2.7 ^a	59±3.3 ^a	60±0.8 ^a	90±6.1 ^A	62±3.4 ^A	59±2.8 ^A	81±1.1A	87±6.4A
<i>E. faecalis</i> A8	58±2.7 ^a	52±2.1 ^b	36±2.1 ^c	92±5.9 ^A	80±2.5 ^A	79±1.1 ^A	79±1.6A	88±6.8A
<i>E. faecalis</i> A9	56±3.1 ^a	49±3.0 ^a	34±1.9 ^b	90±9.1 ^A	78±2.1 ^A	59±2.8 ^A	75±1.6A	88±7.3A
<i>E. faecalis</i> A10	76±0.9 ^a	75±1.5 ^a	46±2.9 ^b	87±9.5 ^A	73±1.8 ^A	60±3.7 ^A	83±1.0A	88±7.6A
<i>E. faecalis</i> A11	63±2.8 ^a	60±2.1 ^a	48±3.1 ^a	84±9.4 ^A	50±2.6 ^B	48±1.8 ^C	76±1.2A	89±7.0B
<i>E. faecalis</i> A12	63±1.5 ^a	46±3.2 ^a	36±1.1 ^b	83±1.3 ^A	60±1.5 ^B	61±1.4 ^A	85±6.8A	89±6.9A
<i>E. faecalis</i> A13	36±2.1 ^a	23±2.1 ^a	23±1.1 ^b	84±1.0 ^A	62 ±3.4 ^A	62 ±2.9 ^A	79±1.0A	88±5.9B
<i>E. faecalis</i> A14	63±6.5 ^a	58±1.9 ^a	61±2.9 ^a	92±5.6 ^A	67±2.2 ^B	69±1.6 ^C	87±6.7A	90±5.6A

* Mean values (±standard deviation) in the same row flanked by at least one common letter showed no significant (P>0.05) differences. Superscript letters refer to the treatment with pepsin at pH 2; superscript capital letters refer to the treatment with pepsin at pH 3; capital letters refer to the treatment with pancreatin.

Table S3. Antibacterial activity of LAB strains against target pathogenic bacteria.

<i>LAB strain</i>	<i>S. aureus</i>	<i>S. epidermidis</i>	<i>M. luteus</i>	<i>E. coli</i>	<i>L. monocytogenes</i>	<i>P. aeruginosa</i>	<i>E. faecalis</i>	<i>S. Typhimurium</i>	<i>B. cereus</i>	<i>V. parahaemolyticus</i>
<i>A1</i>	++	++	++	++	+	-	++	++	+	+
<i>A2</i>	++	++	++	++	+	+	++	-	-	+
<i>A3</i>	++	++	++	++	+	+	+	-	-	-
<i>A4</i>	++	++	-	+	++	+	++	+	+	+
<i>A5</i>	++	++	+	+	+	++	++	+	+	+
<i>A6</i>	+	++	-	+	++	++	++	+	+	+
<i>A7</i>	++	++	+	+	++	++	++	+	+	+
<i>A8</i>	++	++	+	+	++	++	++	+	+	+
<i>A9</i>	++	++	+	+	++	++	++	+	+	+
<i>A10</i>	++	++	+	+	++	++	++	+	+	+
<i>A11</i>	++	+	-	+	++	+	+	+	+	+
<i>A12</i>	++	++	+	+	++	++	++	+	+	+
<i>A13</i>	++	+	+	+	++	++	+	+	-	+
<i>A14</i>	++	-	+	+	++	++	+	-	-	+

(-): no inhibition, Ø of inhibition zone <4 mm; (+): 4<Ø<10 mm; (++): Ø>10 mm

Table S4. Anti-biofilm activity* of LAB strains against target pathogenic bacteria.

LAB strain	<i>S. aureus</i>	<i>S. epidermidis</i>	<i>M. luteus</i>	<i>E. coli</i>	<i>L. monocytogenes</i>	<i>P. aeruginosa</i>	<i>E. faecalis</i>	<i>S. Typhimurium</i>	<i>B. cereus</i>	<i>V. parahaemolyticus</i>
A1	63±3.0 ^{ab}	51±2.4 ^b	68±1.4 ^a	68 ±9.9 ^{ab}	76±8.4 ^a	65±3.2 ^b	43±3.6 ^c	46±3.6 ^b	86±5.1 ^a	88±2.7 ^a
A2	69±8.3 ^{ab}	53±8.6 ^{ab}	65±2.0 ^a	55±2.4 ^b	73±2.8 ^a	52±3.4 ^c	62±1.5 ^b	50±0.5 ^b	88±4.0 ^a	89±2.0 ^a
A3	56±2.6 ^b	47±1.8 ^b	71±2.3 ^a	45±19.0 ^b	70±1.1 ^a	80±1.3 ^a	50±4.0 ^{bc}	55±3.6 ^b	87±6.9 ^a	87±3.3 ^a
A4	69±7.4 ^{ab}	72±8.3 ^a	76±2.2 ^a	74±1.3 ^{ab}	46±1.3 ^b	71±3.4 ^{ab}	77±7.8 ^a	48±1.1 ^b	86 ±2.7 ^a	83±7.4 ^a
A5	74±0.0 ^a	78±2.1 ^a	81±1.8 ^a	76±6.2 ^a	42±1.2 ^b	82±1.1 ^a	66±2.0 ^a	49±4.9 ^b	83±4.0 ^a	84±1.0 ^a
A6	65±1.8 ^{ab}	50±8.1 ^b	75±3.1 ^a	75±1.8 ^{ab}	40±1.8 ^b	84±5.6 ^a	51±3.2 ^{bc}	63±3.0 ^a	80±8.7 ^a	83±6.0 ^a
A7	63±5.4 ^{ab}	58±7.7 ^{ab}	78±2.1 ^a	87±1.7 ^a	51±1.7 ^b	74± 9.4 ^a	73±9.4 ^a	59±1.0 ^a	82±3.2 ^a	82±6.9 ^a
A8	54±1.6 ^{ab}	67±1.9 ^a	74±2.2 ^a	62±2.9 ^b	59±1.2 ^b	66±1.2 ^b	72±1.6 ^a	45±7.7 ^a	82±4.6 ^a	86±7.7 ^a
A9	64±2.4 ^{ab}	67±6.5 ^a	73±2.8 ^a	76±1.3 ^{ab}	63±8.3 ^a	74±6.1 ^a	72±3.4 ^a	58±5.5 ^a	84±4.7 ^a	85±9.6 ^a
A10	64±6.1 ^{ab}	55±1.6 ^b	69±3.0 ^a	71±2.5 ^b	38±9.8 ^b	69±1.3 ^b	71±4.2 ^a	71±1.4 ^a	83±2.4 ^a	81±9.6 ^a
A11	56±1.7 ^b	53±1.6 ^b	67±3.4 ^a	76±1.4 ^{ab}	31±1.1 ^c	72±5.0 ^{ab}	77±1.1 ^a	59±0.3 ^a	77±6.3 ^a	76±6.6 ^a
A12	76±6.5 ^a	68±2.2 ^a	73±2.4 ^a	73±1.1 ^b	53±4.2 ^{ab}	77±7.6 ^a	62± 1.7 ^b	59±2.3 ^a	78±8.7 ^a	83±4.9 ^a
A13	64±1.0 ^{ab}	75±2.0 ^a	72±2.7 ^a	75±1.7 ^{ab}	37±4.3 ^b	73±9.2 ^a	49±8.7 ^{bc}	74±1.0 ^a	76±9.8 ^a	81±2.9 ^a
A14	68±3.9 ^{ab}	64±5.0 ^a	76±2.4 ^a	74±1.6 ^{ab}	35±9.4 ^b	67±3.3 ^{ab}	75±1.1 ^a	66±2.1 ^a	71±1.3 ^b	82±5.7 ^a

* Values in the same column with at least one common letter (a-c) showed no significant (P>0.05) differences.